June 14 (Reuters) – Eli Lilly and Co: * LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)